P. Chua

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

RXDX-107, A Dodecanol Alkyl Ester of Bendamustine, Demonstrates GreaterStability and Broad Antitumor Activity in Multiple Pre-Clinical Models of SolidTumor

R. Shoemaker, E. Tindall, Michael H. Johnson, 2016 .

Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase

A. Minchinton, A. Kyle, G. Winters, 2013 .